Immunome’s (IMNM) “Overweight” Rating Reaffirmed at Stephens

Stephens restated their overweight rating on shares of Immunome (NASDAQ:IMNM) in a research note released on Thursday,Benzinga reports. Stephens currently has a $30.00 price objective on the stock.

IMNM has been the subject of several other reports. Lifesci Capital assumed coverage on Immunome in a report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price objective for the company. Guggenheim dropped their price objective on Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a report on Thursday. Finally, Wedbush reaffirmed an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a report on Monday, March 10th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Immunome has an average rating of “Buy” and an average price target of $25.50.

Immunome Trading Down 5.5 %

NASDAQ:IMNM opened at $8.18 on Thursday. The stock has a market cap of $652.58 million, a P/E ratio of -1.01 and a beta of 1.93. The stock has a 50 day simple moving average of $9.76 and a 200 day simple moving average of $11.55. Immunome has a 1-year low of $8.17 and a 1-year high of $26.70.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The company had revenue of $2.74 million during the quarter, compared to analyst estimates of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. As a group, sell-side analysts forecast that Immunome will post -2.21 EPS for the current year.

Insider Transactions at Immunome

In other Immunome news, CEO Clay B. Siegall purchased 150,000 shares of the stock in a transaction dated Friday, January 31st. The stock was bought at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the acquisition, the chief executive officer now owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. This represents a 28.87 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 8.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Immunome

A number of institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. raised its holdings in shares of Immunome by 6.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company’s stock worth $359,000 after buying an additional 1,520 shares in the last quarter. Sequoia Financial Advisors LLC grew its position in Immunome by 11.7% during the 4th quarter. Sequoia Financial Advisors LLC now owns 19,065 shares of the company’s stock worth $202,000 after acquiring an additional 2,000 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its position in Immunome by 5.1% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 41,505 shares of the company’s stock worth $441,000 after acquiring an additional 2,005 shares during the last quarter. Intech Investment Management LLC grew its position in Immunome by 26.5% during the 4th quarter. Intech Investment Management LLC now owns 18,961 shares of the company’s stock worth $201,000 after acquiring an additional 3,974 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in Immunome by 3.5% during the 4th quarter. Wellington Management Group LLP now owns 145,564 shares of the company’s stock worth $1,546,000 after acquiring an additional 4,874 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.